This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HIV/AIDS

CD36 (GPIV)

In vitro studies suggest anti-CD36 antibodies could help treat HIV. In HIV-infected macrophages, an anti-CD36 mAb or siRNA decreased the release of HIV p24 from the macrophages, which facilitates the spread of the virus, compared with an isotype mAb or control siRNA. In HIV-infected macrophages cocultured with T cells, the anti-CD36 antibody decreased the fraction of infected T cells compared with isotype mAb. Next steps include identifying a humanized antibody against CD36.
Arteria S.A. has the CD36 inhibitor AP-5258 in preclinical testing to treat dyslipidemia.

SciBX 6(47); doi:10.1038/scibx.2013.1355
Published online Dec. 12, 2013

Patent application filed; licensing status unavailable

Berre, S. et al. J. Exp. Med.; published online Oct. 21, 2013;
doi:10.1084/jem.20130566
Contact: Philippe Benaroch, Curie Institute, Paris, France
e-mail:
benaroch@curie.fr